Programming for the upcoming ACS National Meeting in Boston, MA

DIVISION OF BUSINESS DEVELOPMENT AND MANAGEMENT

M. Hurrey, Program Chair

Sunday, August 22, 2010  Job Growth in This Economy?

12:55 pm         

Introductory Remarks

Dr. Mick Hurrey

1:00 pm

Dr. Patrick Connelly

Pharmaceutical Communities: Making Drugs, Protecting Jobs, and Building a Local Economy of Scale

Pharmaceutical firms that outsource development and manufacturing to contract organizations frequently seek out the lowest bidder, even if this means coordinating a large network of partner organizations or centralizing operations at a single, integrated partner overseas. A third, ultimately more cost-effective option would prioritize long-term growth in efficiency and value over short-term cost-cutting. This approach draws on the potential of a region rich in pharmaceutical companies, like metropolitan Boston. The agglomeration of successful firms around Boston acts as a Porter cluster, a kind of local economy of scale in which the proximity of competing firms, suppliers, and contract organizations contributes to increased productivity and innovation. Key to maximizing the flexibility and creative capacity of Boston’s pharmaceutical cluster is a new type of contract organization, the integrated local CMC service provider (ILCP). The ILCP would be located near its partner companies, like a small specialty organization, but offer fully integrated, “soup to nuts” services like an overseas firm. While the ILCP would not attempt to compete on price alone with the latter, its reciprocity and long-term relationship-building with each contracting firm would allow pharmaceutical companies to benefit from efficient collaboration, from the accumulation of technical knowledge over time, and from a flexible, variable cost structure that is not practically attainable with in-house departments.

1:20 pm
Dr. Doug Mendenhall

LOCAL vs. CENTRAL:  A Conundrum for CDMO’s

As the economics of big pharma dramatically shift to favor variabilized outsource costs over full internal capabilities in the CMC domain, the CDMO industry finds itself presented with a unique opportunity to expand its scope to fill this need.    To fully realize this opportunity, it is becoming increasingly obvious that a full front-to-back model, eliminating hand-off inefficiencies and ensuring continuity of ownership, provides the most attractive option especially for the strategic relationships that in the end are most favorable to both parties instead of the inefficient transactional interactions that have dominated the past “spot-market” approach to outsourcing.    This same full service strategic model can also be most attractive to smaller firms if thoughtfully structured to anticipate increasing head-to-head competition in narrow therapeutic areas as pharma also effectively pushes more of the discovery phase of their activities to often leaner and faster start-ups for target identification/validation and candidate evaluation through critical go/no-go clinical POC decisions.   Nimbleness to move forward the successful NCE survivors into larger clinical trials and commercialization will then predictably be a new and differentiating competitive dimension to maximize asset value and buyer return.    An effective interface with less mature, often “first time” start-ups, however, requires a different approach that accommodates their need for faster turnaround and regular face-to-face/hands-on interactions that can only practically happen on a local basis.  The conundrum then for a large CDMO—capable of delivering the essential downstream benefits of such a model—is how to provide this local touch effectively while preserving the necessary central economies of scale that both big and large customers continue to demand as the cost and value funnel rapidly expands on the back end.    The approach that Patheon, one of the largest CDMO’s, is taking to resolve this dilemma will be discussed.

1:40 pm

Dr. James Evans and Dr. Allan Myerson

Continuous Manufacturing of Small Molecule Pharmaceuticals: The Ultra-Lean Way of Manufacturing

We describe the motivation for and vision behind the Novartis-MIT Center for Continuous Manufacturing.  In particular, we discuss continuous manufacturing as the ultimate in lean manufacturing with quantified and fully integrated processes.  We also present a cost analysis based on a case study and discuss the challenges behind continuous manufacturing of pharmaceuticals.

2:00 pm

Dr. Susan Windham-Bannister

Importance of Local Communities in US Job Creation

Keeping jobs in American communities is an urgent priority at every level of government. To this end, the public sector should encourage initiatives, like local clinical-supply manufacturing, that build solid, lasting relationships among local businesses. These relationships make our businesses more durable and, therefore, more competitive over the longer term. The best competitors, after all, are the best employers.

2:20 pm

Dr. Michael Kaufman

Special Challenges in the Outsourced Manufacture of Oncology Drugs

The pharmaceutical development of anti-cancer agents differs in many important ways from the development of non-oncology drugs.  From a CMC perspective, some important aspects of oncology drug development are the possibility of an NDA filing based on Phase 2 data, and the general inability to test dosage form changes (‘bridging studies’) in normal healthy volunteers.  Both of these factors suggest that the development of CMC processes needs to occur in a rapid fashion relative to non-oncology drugs, despite the somewhat higher attrition rate of oncology agents.  In addition, many anti-cancer drugs are cytotoxic and may require special isolation procedures, dedicated equipment, and built-for-purpose facilities.  All of these factors make the outsourcing of oncology clinical trial material (CTM) manufacture a highly challenging endeavor.  In this talk, we will survey the capabilities of third-party suppliers in cytotoxic drug development, point out some of the more crucial gaps in CMO coverage, and discuss resulting opportunities for collaboration.

2:40 pm
Dr. Ed Price

Navigating the Critical Path: Transferring Technology to a Contract Manufacturing Organization (CMO)

Process Development and technology transfer is much more than simply optimizing a process to achieve ideal chemistry. What often works best is if scientists on both sides communicate directly to ensure an accurate transfer of the technology. Anyone that has been in the CMO environment has stories of extremely successful transfers, as well as ones that became nightmares. In practice many technical packages provided to a CMO often times do not provide enough detail or simply the quantity of the required information is lacking. Some examples include the number of times the procedures have been performed, the largest batch size produced, or the level to which the analytical methods have been developed. Besides the quantity, also the quality of the information to be provided is very important. Does the technical package contain detailed information on experiments that where not successful, as well as the ones that were successful? Has the purity information been collected by a single validated HPLC method or has the purity information been collected with several different methods? Often times spending a little extra time and effort on few key items can lead to a much smoother and successful technology transfer.

3:00 pm
Dr. Dan Coughlin

The Development of New Technologies for Contract Chemistry Providers.  Addressing the Chemistry Complexity of the Evolving NCE Landscape

As the pharmaceutical industry heads towards increasing degrees of molecular complexity in their drug candidates under development, the need for the application of newer chemistry technologies to synthesize these candidates becomes more important. For API chemistry service providers it is important to develop and provide a broad range of these newer technologies in order to be competitive in the demanding modern market for such services. Particularly, the need to address complex chiral chemistry in the chemistry service market will be discussed. Technologies such as asymmetric catalysis, biocatalysis and large-scale chiral separations are important tools to supplement more traditional methods for the synthesis of chiral drug molecules.

This presentation will focus on the development and integration of these newer chiral synthesis technologies to address the evolving drug development market. The ability to couple these technologies within a large-scale API manufacturing campaign will be explored. The competitive importance of the identification and implementation of technologies for the future will also be discussed as well the relevance of these niche technologies to the local CMC service market.

3:20 pm

Panel Discussion

4:00 pm

Cocktail and Networking Reception

Monday, August 23, 2010  Open-Source Drug Discovery

8:30 am           

Introductory Remarks

Richard Harper and Bernard Munos

8:35 am

Dr. Samir Brahmachari

Open Innovation: A Novel Approach to Collaborative Research for Global Good

From ancient times India had been a champion of open innovation. India has now adopted the TRIPS regime and CSIR is spearheading the patenting of new products and processes. Admittedly, a market-oriented research incentive does not work for diseases that lack market. Therefore we should ask: Can Open Source Drug Discovery address global healthcare challenges in infectious diseases?

When it comes to providing drugs for tropical diseases, what needs be addressed is affordability. Neglected diseases, such as tuberculosis, malaria or leishmaniasis, affect the poor. If drugs must be made affordable to the poor, exclusivity in the marketplace alone should not be the key guiding principle.

Can we combine the strengths of chemists in synthesizing new molecules, the insights of the biologists, the skills of informaticians on one collaborative platform to reduce the costs of discovery, and at the same time provide micro-attribution to the contributions of each and everyone? Can we use the existing business models of contract research on an open public-private partnership mode with regular feedback to the scientific community to reduce the cost of development process including clinical trials? The Open Source Drug Discovery model (www.osdd.net) provides an alternative model of innovation for drug discovery.  CSIR-led Team India Consortium with global partnership has pioneered this approach for the development of affordable drugs through Systems Biology approach for tuberculosis. The details of this will be presented.

9:05 am

Dr. Christopher Austin, M.D.

The New Ecology of Collaborative Pharmaceutical Research

Over the last decade, remarkable changes have occurred in the science, processes, and economics of drug development, bringing about a realignment in the traditional roles of the public and private sectors in drug development.  At NIH, the Molecular Libraries, Therapeutics for Rare and Neglected Diseases, and Rapid Access to Intervention Development programs, among others, have brought technologies and expertise into the public sector that were previously only present in biopharmaceutical companies.  A firmly precompetitive space for early phase (target to lead) small molecule research has been established, fostering the development of chemical biology, chemical genomics, and cheminformatics research that are defining gene, protein, and pathway functions in unprecedented detail, and continually expanding and redefining druggable genome space.  With the Human Genome Project and related initiatives identifying the genetic causes of an unprecedented number of rare diseases, the continuing scourge of tropical diseases, and the retrenchment of the biopharma industry leading to decreased drug development activity on even more common diseases, NIH and other public agencies have recognized the opportunity and the imperative to develop innovative and collaborative later stage (preclinical and POC human) drug development programs, particularly for rare and neglected diseases.  The successes, lessons, and ongoing challenges of this historic realignment in drug discovery will be discussed, through the lens of the NIH programs working in this area.

9:35 am

Dr. Solomon Nwaka

Producing drug innovation on a shoestring: innovation networks for neglected diseases

For the last 10 years, WHO/TDR has been in the vanguard of pharmaceutical innovation as it helped fostered the creation of public-private partnerships to pioneer novel approaches for research in neglected diseases. These organizations now boast attractive pipelines of projects, and several have brought drugs through clinical development and into the market. More importantly, they have demonstrated the capability to develop drugs at lower costs. Armed with this experience, WHO/TDR has just launched an even more ambitious project, which is to unite the disparate biomedical research infrastructure across Africa into a continent-wide network that can discover and develop novel health products for diseases that disproportionately affect Africa. This presentation will review the challenges and opportunities in implementing public-private partnerships, and will discuss their relevance in health product innovation.

10:05 am         

Intermission

10:20 am

Dr. F Javier Gamo

GSK's approach to open source malaria drug discovery

In its aim to work in partnership and encourage research in neglected tropical diseases, GlaxoSmithKline has released structures and data on more than 13,500 antimalarial inhibitors found in its screening compound library.
GSK has tested the 2 million compounds present in the corporate library used routinely for HTS in a whole-cell screening approach using the 3D7 P. falciparum strain. The screen has yielded 13,533 compounds inhibiting parasite growth more than 80%. This set has been named TCAMS (Tres Cantos Antimalarial Set).
Additional experiments, like activity against P. falciparum resistant strains or activity against the hepatoma HepG2 cell line as surrogate of cytotoxicity, have been performed to add knowledge to the TCAMS. Also, using the proprietary information existing in our databases, a prediction of the putative antimalarial target has been made for those compounds with available data.
In order to encourage further research by the larger malaria community on the cellular targets and mode of action of the compounds, we have made public the chemical structures of the compounds in TCAMS, together with the above mentioned data.
All the information is publicly available at the URL: http://www.ebi.ac.uk/chemblntd and ideally, this could be a world-wide chemical genomics approach to better understand the druggable genome of P. falciparum. It is the first time to our knowledge that a pharmaceutical company has made public the structures of so many proprietary compounds in the hope that it could lead to the development of new and innovative treatments for malaria.

10:50 am
Dr. Alpheus Bingham

Innovating in drug innovation:  what’s next?

Since the 1990s, Dr. Bingham has pioneered many of the innovations that are helping redesign drug R&D.  InnoCentive and Chorus, which he founded while leading the eLilly division of Eli Lilly, are two of his lasting contributions.  Now retired and full-time innovation thinker, scholar, and entrepreneur, he is actively involved in creating another generation of tools that will take drug innovation to the next frontier.  His presentation is a peek on things to come.

11:20 am

Panel Discussion

12:00 pm

Adjourn Morning Session

1:30 pm           

Introductory Remarks

Richard Harper and Bernard Munos

1:35 pm
Mr. Bernard Munos

The compelling economics of open innovation for drug R&D

We are in the midst of a scientific renaissance that is yielding unprecedented insights into pathology, but these discoveries are not translating very well into new therapies.  The cost of developing new drugs, which is estimated to be billions of dollars apiece, is limiting the number of projects that can be funded.  Those that proceed through development and registration face increasing resistance from payers when they reach the market.  These costs pressures have been even harsher in areas that offer limited commercial prospects such as rare diseases, biodefense, and the diseases of poverty.  Yet, the challenge of producing treatments for these neglected areas has encouraged scientists and entrepreneurs to come up with alternative R&D models that are often based on the networked architecture that is characteristic of open innovation.  We now have a growing body of data to compare the economics of traditional and open innovation models.  This presentation reviews the figures that make open innovation a compelling option.  It also discusses the profound transformation that awaits organizations wishing to embrace it, and its implications for the pharmaceutical industry.

2:05 pm
Dr. Zakir Thomas

OSDD: Making Open Innovation Work

The Open-Source Drug Discovery (OSDD) is global scientific community of more than 3000 persons from 74 countries that was launched in September 2008 by India’s Council for Scientific and Industrial Research (CSIR).  OSDD facilitates collaboration among biologists, chemists, bio- and chemo-infomaticians, mathematicians, software professionals, management professionals and others.  www.osdd.net is a web 3.0 portal which facilitates that collaboration. It has several ongoing projects such as identifying drug targets and inhibitors.  It has already yielded an early hit that is being taken forward.  OSDD also has set up a small molecule library for screening against Mtb, In December 2009, OSDD announced an open-source ‘Connect-to-Decode’ project to reannotate the entire Mtb genome.  About 800 researchers signed up to collaborate. The task was divided into five themes that covered gene ontology, protein-structure, interactome/pathways, glycomics and the immunome annotation. In a span of less than four months, these highly motivated contributors completed the task under the guidance of experienced scientists.  This talk will explain the basic concepts of OSDD and take you through the process followed in this highly challenging open collaboration model.

2:35 pm
Dr. Marta Pineiro-Nunez

Lilly’s phenotypic drug discovery Initiative Work

The Lilly Phenotypic Drug Discovery (PD2) Initiative is a novel open innovation program that seeks to engage researchers worldwide in the identification of novel compounds that have potential to be developed into drug candidates for key areas of disease focus. Since its launch in June of 2009, PD2 has been well received by scientists and technology transfer professionals alike.  To date, more than 140 institutions around the globe have become affiliated with the program and numerous compounds have been evaluated in the phenotypic disease modules.  My presentation will describe the scientific rationale behind PD2 , the business model and operational details.  Additionally,  metrics collected to date that describe the performance of the program will be shared.

3:05 pm
Dr. William Scott

Distributed Drug Discovery (D3): Linking Basic Research and Education to Find Drug Leads for Neglected Diseases

This seminar will discuss the concept of Distributed Drug Discovery (D3) and how it adapts basic research to enable, on a global scale, the simple, reproducible and inexpensive synthesis of many potential drug-lead molecules for neglected diseases. D3 has created and published open-source virtual catalogs containing biomimetic molecules accessible by simple and reproducible synthesis in academic laboratories across the world. We have demonstrated this synthetic capability in Indianapolis (USA), Moscow (Russia), Barcelona (Spain) and Lublin (Poland). Collaborators can access these virtual catalogs. When computational analysis identifies promising molecules from them, they can then be readily made by undergraduate students in a distributed fashion. This open-source, integrated process of Distributed Drug Discovery facilitates a direct link between education and drug lead discovery for neglected diseases.

3:35 pm
Dr. Sean Ekins

Collaborative Drug Discovery: A platform for transforming neglected disease R&D and beyond

Collaborative drug discovery (CDD) is a new approach to biomedical research that uses a web-based software to host and share multiple kinds of databases. The community currently using CDD includes leading researchers working on neglected diseases such as malaria and tuberculosis. It uses CDD as a repository for public and private data on Mycobacterium tuberculosis, and to enable data-mining and collaborations by the scientific community. For instance, after capturing well over 300,000 molecules and related data from patents, literature and high throughput screens (making it the largest publicly available Mtb database), our team has used the CDD tools and functionalities to gain novel insights into the molecular properties of compounds active against this pathogen.  Pharmaceutical R&D could leverage this approach, and use CDD software and researcher networks to tackle other neglected as well as mainstream diseases.

4:05 pm           

Panel Discussion

5:05 pm           

Reception and book signing for The Future of the Chemical Industry

Tuesday, August 24, 2010  Chemistry:  The Future-proof Profession

8:00 am           

Introductory Remarks

Ms. Carol Duane, Organizer

8:10 am

Dr. Nancy Gray

Once a Chemist, Always a Chemist?

This presentation will focus on the circuitous career path of the speaker that wound from basic chemical research in the oil industry to the position of Director and CEO of the Gordon Research Conferences. Highlights of presentation will include brief career stints developing expertise in counting the number of Common Murres (seabirds) on Alaskan outcrops to becoming the “Queen of Slime and Pithy Phrases” managing a national public outreach program, to her eventually ascent to the ranks of senior management in the world's largest scientific society (the ACS, of course). Insights will be provided regarding whether passing p-chem prepares an individual to balance a multi-million dollar budget and whether chromatography can be used to separate out high performing from underperforming individuals during employee evaluations. The speaker will share her thoughts on the skills and competencies needed to succeed “on the fringe of science” and reveal all the things she “knows now but wished she knew then” about navigating through a non-traditional - and highly enjoyable - career path.

8:40 am

Dr. Sunny Tang

From Chemistry to Finance to Philanthropy: An Unplanned Journey

To transition from being a Shell scientist one day to a financial advisor the next, seems rather drastic and unnatural. However, my transition was neither abrupt nor particularly difficult, and the right chemistry certainly had a great deal to do with it. To transition from money management to philanthropy, on the other hand, was difficult and painful, and it's debatable whether chemistry had anything to do with it.

9:10 am

Dr. Carolyn Fisher

Love Food as Well as Chemistry? Combining Passions with Chemistry for a Successful Career

Know yourself, discover your passion, and weave it into your career! I have combined my passions for food and teaching with my role as a chemist and built a successful career in the Food and Flavor industry; you can do it too. I hope that by describing my path from Research Chemist at Kalsec to writing the book Food Flavours: Biology & Chemistry to my roles at McCormick, I can spark your ideas of how to weave your passions into your career. For example, as part of my industrial career, I have been able to develop a training program for regulatory professionals internally within the U. S. Industrial Group at McCormick as well as externally in a short course on Food Labeling Requirements and Implications for Foods Marketed in the U.S.

9:40 am

Dr. Benjamin Chaloner-Gill

Business Development: A Viable Career Path for Chemists

Without my technical background (Ph. D. Chemist), my current role in technology and new business development may not have occurred. The problem solving skills learned and refined in graduate school laid the foundation for my career – independent of industry. In my journey from the bench to the business world, I have had very different roles – scientist, program and project leader, process engineer, chief technical officer, technical marketing, and vice president of business development. Within each change, my business role increased by my choice. My chemistry background gave me the ability to be knowledgeable in the various industries, which for me have spanned battery materials, nanotechnology, photovoltaics, pharmaceuticals and oil/gas. My pathway from the lab to the business and how my chemistry background has enabled this will be presented.

10:10 am
Dr. Margaret Cavanaugh

What Sustainability Means to Me

Chemistry has led me to a senior management position in the federal government--something I never envisioned when I was early in my career. I work at the National
Science Foundation on research and education programs in the geosciences that deal with climate, environmental hazards, and many other topics in ocean, earth, and atmospheric sciences. Currently, I am working on developing programs related to sustainability --- the nexus of environmental, energy and economic issues for the future. This presentation will be about sustainability --- both in a career and in the larger world!

10:40 am
Dr. Jurgen Exner

A Chemist’s Tale: Research to Global Environmental Consulting

I will describe my winding career path leading to the formation and operation of a consulting company working on world-wide environmental issues that ranged from Times Beach, MO, to Bhopal, India, and the Middle East. This path included stops at fundamental research, technical sales, engineering and production, senior management at large environmental companies, market assessment, accounting, and development of new businesses.
Training in chemistry allowed me to deal with the fascinating multi-disciplinary challenges of people, technology, markets, economics, legal constraints, and public understanding.

11:10 am
Dr. Anthonie Lombard

Engineering and Chemistry: Miscible, Energetic, Explosive?

During the (persistent!) "Great Recession" many chemists as well as engineers and other scientists found themselves in the unenviable position of not only finding a new occupation, but also having to change disciplines. Although this situation posed many challenges for the individuals concerned, it also provided excellent opportunities for unlocking innovative potential in the individuals and also their new organizations. Much has, for example, been
written and said about the "Medici Effect". I will discuss some real life examples of this effect being put into practice.

11:40 am

Adjourn Morning Session

2:00 pm

Opening Afternoon Session

Ms. Carol Duane

2:05 pm
Ms. Bonnie Lawlor

A Chemical Education: Gaining Common Skills for Uncommon Opportunities

A degree in chemistry offers unlimited career possibilities. No matter what career path one follows initially, life will present many unexpected and surprising opportunities. The core skills that are learned while studying chemistry provide a basic toolkit for successfully leveraging some of life's opportunities - scientific deduction, problem solving, unfailing pursuit of answers, attention to detail, etc. – all are applicable outside of chemistry. Those skills, combined with other personal talents and passions, lay the foundation for a fulfilling and varied professional life. This presentation will discuss one chemist's odyssey from the lab to publishing to running a trade association – all fueled initially by a chemical education.

2:35 pm
Mr. Joe Stoner

A Chemist’s Skills Lead to Success in the Non-Profit Sector

The presenter will document his career journey from being a successful analytical instrument salesman and sales manager to running a Habitat for Humanity affiliate as its Executive Director. He will talk about the thought process that led him to seek employment in the non-profit sector. He will explore the skills that are transferable from a career in the chemical industry to that of the non-profit world. He will review the specific steps
that he took to make this remarkable transition.

3:05 pm
Dr. Peter Dorhout

Chemists Without Laboratory Borders: Alternative Careers in Research Administration

Chemists are trained in the fundamentals of our science and the rigors of the Scientific Method, but how do these translate into a career in science or science administration? Cynthia Robbins-Roth's 2006 book on "leaving the Ivory Tower" compiles a wonderful set essays on the alternative careers in science, and this presentation will focus on several of her examples as well as a personal transition from a successful career in academics into a new career in research administration and the minefield of negotiating with former peers, research compliance, and sponsored program administration in a shared governance environment.

3:35 pm
Dr. Brian Crawford

Scientific Publishing: The (Not So) Accidental Profession

Drawing on a professional career that began with scientific research and teaching, followed by more than two decades spent in scientific, technical, and medical publishing, the author will outline alternative career paths for today's science professionals who are intrigued by the prospect of shaping the global scientific information industry of tomorrow. Whether drawn
to mission-oriented service in the not-for-profit sector or to the range of opportunities presented by the commercial publication of journals, books, and databases, trained scientists can apply their skill sets to enable novel research discoveries and underlying data to be assembled, vetted, edited, marketed, sold, and delivered to research professionals—and to ensure that the significance of those discoveries is better understood by students and the
interested public. Challenging the popular assertion that publishing is the “accidental profession,” this talk will describe how chance favors the prepared mind—and how a solid grounding in the scientific method, combined with certain personal attributes, can position one for a range of rewarding publishing roles and provide for a lifelong intellectual engagement with science.

4:05 pm
Dr. Cheryl Martin

With a Foundation of Chemistry Anything is Possible!

What activities do you undertake when you are not working or studying? What do you
dream about doing? What are your strengths? Which accomplishments do you feel good about? Marrying your individual answers to questions like these with your degree in chemistry can make for a very exciting, fulfilling and unique career path. Networking and remaining open to novel challenges play critical roles in opening up new opportunities as well. Personal experience leveraging chemistry skills through marketing, finance, management and consulting will be shared.

4:35 pm           

Panel Discussion

5:05 pm           

Adjourn Afternoon Session

“Just Cocktails”

WCC Networking Reception for Mid-Career Chemists

4:30 PM – 6:30 PM, Sheraton Boston – Republic Ballroom A
WCC, co-sponsored by BMGT and SCHB

Wednesday, August 25, 2010  Open Innovation:  The New Paradigm for Competitive Advantage

9:00 am           

Introductory Remarks

Dr. Dan Daly

9:05 am

Dr. Gene Slowinski

Implementing Open Innovation; road warrior or road kill, it’s your choice

To compete effectively in today’s business environment, firms are using strategic alliances to link their technical resources with world-class commercialization partners.  Unfortunately, many joint development alliances fail.  Managers must deal with the complexities of cooperatively developing intellectual assets, linking decision-making structures and building cross-corporate innovation networks.   Dr. Slowinski’s 25 years of work on over 300 technology-based alliances led him to identify key best practices.  He will present a set of simple, but powerful management tools and metrics.  Many firms use these tools to increase the value of both their individual alliances and their R&D alliance portfolios.  What you will learn:

• Implementing “Open Innovation” using the “Want, Find, Get, Manage” Framework.

• The Alliance Framework; a rigorous, structured approach for creating technology-based alliances

• Chemical industry alliances (who is doing what to whom, and why)

• Tools, metrics, and management techniques for implementing alliances

• Special problems in collaborative R&D alliances

• What’s next in the world of Open Innovation

9:50 am

Dr. Martin Mascianica

Bringing Sustainability to Open Innovation

Technology-based based companies of every size have traditionally utilized a division of labor to make innovation gains.   R&D teams were tasked to conceptualize the essence of novelty and to reduce discovery to practice, while business development and manufacturing teams were charged with delivering an offer along with a product or solution to a customer base.   The traditional innovation model has become non-functional in the minds of many, and has been replaced by a rather diverse set of open innovation approaches each with a goal of optimizing creativity and yielding meaningful results.  Practicing this open innovation is deemed effective, as evidenced by the many open innovation success stories shared in the business and scientific community today.  The question is how does an enterprise or institute sustain the success of an “open innovation” platform?  The presentation will provide an industry perspective on bringing sustainability to open innovation industrial environment.

10:20 am

Dr. Ronald Taylor

Manage Your IP Well to Win the Open Innovation Race

The R&D world changed forever when the “not invented here” syndrome was replaced with the “invented anywhere approach”.  As firms in the chemicals industry and other technology segments move rapidly to a model in which they complement their internal innovation efforts with innovation from external sources, they need to manage their intellectual property carefully, moving quickly with external technology providers while still protecting their IP rights.  This requires careful alignment and appropriate negotiations of non-disclosure and joint development agreements, with timing that maintains intellectual property rights.  Moving too soon can expose the firm to contamination, but waiting too long can result in a loss of the fruits of the collaboration.  Firms that manage their intellectual property rights conscientiously will win the competition in an Open Innovation environment.

10:50 am

Dr. Gabriel S. Eichler

InnoCentive’s Open Innovation Rapid Adoption Methods and Practices (ONRAMP) Program

The initial practice and continual execution of Open Innovation is a challenge for most organizations. The managerial complexity of coordinating top-down leadership with grassroots organization-wide support can slow down or even kill internal efforts to adopt most open methods of innovation. To address this challenge InnoCentive has identified and refined the best practices from its leading and most successful clients and created a comprehensive suite of workshops under the rubric of ONRAMP. These workshops focus on the critical elements the best practices of process, organization, cultural and infrastructure and provide organization-wide training for everyone from executives, legal professionals, managers and individual Challenge owners. This talk will cover the basics of Open Innovation, InnoCentive and ONRAMP including several key insights from the workshops.

11:20 am
Dr. Hanping Guan

Open Innovation for Long Term Projects

Meeting the increasing global demands for food, feed and fuel requires collaborative innovation among all stakeholders from government agencies to private companies. The stakeholders for agriculture biotechnology are diverse and dynamic. The R&D timeline is long and challenging. Long term collaborative innovation requires shared commitment and shared risks and benefits derived from partnerships. This presentation will focus on two factors key to sustainable collaborative innovation.  First, managing intellectual assets in collaborations could be an important stumbling block for open innovation. Second, managing the expectations and interests of partners and multiple stakeholders is key to the success of collaborative innovation.

11:50 am

Mr. Edward Yokley

Identifying Disruptive Opportunities in the Materials Marketplace: An Example from the Conformal Barrier Coatings Market

Unmet needs in a market space often serve to remove a critical barrier to entry for a supplier to create a disruptive substitute technology. In this work, the structure of market disruption is described along with techniques and tools that can be used to identify opportunities for market disruption. The current state of the conformal barrier coatings market is used as an example to illustrate these techniques and tools.

12:20 pm

Adjourn Morning Session

2:00 pm
Mr. Saul Kaplan

Do organizations continually need to explore, test and experiment with new business models, in the same way they do with new products and technologies today?

Saul Kaplan, Founder and Chief Catalyst of the Business Innovation Factory, argues the answer is yes. For Kaplan the barrier to delivering better value isn’t technology. Humans and our institutions—both stubbornly resistant to change—impede our ability to network people, resources, and capabilities across organizations. Kaplan calls for a safe, manageable environment to explore new business models, a real world test-bed where public and private sector players can innovate collaboratively without disrupting current operations.
“Most organization leaders today have only had to lead a single business model throughout his or her entire career. And most haven’t had to significantly change a business model in order to sustain the organization competitively. Organization leaders of tomorrow will have to change their business model several times over the course of a career and the successful leader will establish an ongoing process to explore new business models, even models that might threaten the current one.”

2:30 pm
Dr. Robin Rogers

Open Innovation and the Faculty Entrepreneur: Opportunities and Perils

Industry and universities have had a growing relationship in the development of new technology from the times of industry cutbacks in research labs and capabilities.  This relationship has led to a growth in technology transfer activities at many universities and the associated growing pains related to the inherent conflicts in the industry and academic research models.  Today, we are seeing an increase in the number of faculty entrepreneurs that wish to capitalize on the development of new technology by founding start-up companies.  The extension of the open innovation model to these start-ups must consider the unique conflicts and opportunities which exist when a faculty member must answer to both their home university and to their growing business.  This presentation will discuss open innovation in light of our efforts to commercialize new ionic liquid technologies in the agrochemical and pharmaceutical sectors via a faculty start-up company, 525Solutions.

3:00 pm

Charlene A. Wall-Warren 

5:00 pm           

Adjourn Afternoon Session